Form4insider filings, from the source

SEC Form 4 · accession 0001209191-18-036926

Karyopharm Therapeutics Inc. · KPTI

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner
Michael Kauffman
Officer — Chief Executive Officer · Director
Period of report
Jun 7, 2018
Accepted (ET)
Jun 11, 2018 · 4:17 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001503802

Table I — non-derivative securities

SecurityDateCodeSharesPriceA/DOwned afterD/INature of ownership
Common StockJun 7, 2018M9,697$0.264A723,207IBy Spouse
Common StockJun 7, 2018M303$0.033A723,510IBy Spouse
Common StockF2Jun 7, 2018S10,000$17.2991D713,510IBy Spouse
Common Stockholding———512,143D
Common StockF3holding———47,309IBy GRAT
Common StockF4holding———47,309IBy Spouse's GRAT

Table II — derivative securities

SecurityConv. / exercise priceDateCodeSharesA/DExercisableExpiresUnderlyingUnderlying sharesOwned afterD/I
Stock Option (right to buy)F5$0.264Jun 7, 2018M9,697D—Dec 15, 2021Common Stock9,6970I
Stock Option (right to buy)F6$0.033Jun 7, 2018M303D—Nov 1, 2020Common Stock3037,553I

Explanation of responses